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INTRODUCTION
HERE is a critical need to better model and understand how the complex interactions between drugs and their targets as well as their pathways contribute to drug efficacy and possible side effects [5] . Complex interactions can be modeled as drug networks contain very crucial information, including their targets, enzymes, carriers, transporters, pathways, diseases, and organisms, as illustrated in Figure 1 . To understand the relations between such entities will help to do the following:
1. Derive better disease treatment and 2) avoid side effects. Takigawa et al [6] summarizes the importance of polypharmacology or drug promiscuity of drug networks because of the following reasons: 1) Exquisitely selective drugs for a single target are likely to exhibit low clinical efficacy and be unsuccessful [7] . 2. Multi-targeted drugs have been clinically successful, particularly as dual or multiplex kinase inhibitors [8] .
3) Many approved drugs, potentially the majority of therapeutic agents, are less selective than initially thought [9] . 4) The robustness of biological systems can be implied by the scale-free nature of drug-target networks [10, 11] . Large datasets are available in both the literature, such as PubChem [12] It is a complex process in terms of both handling available large datasets and developing computational methods for predicting new evolving drug different entity-relations. A recent concentration has been made on drug-target prediction because it can help to reduce the time, cost, and failure rates for developing new drugs. Recently, with the accumulation of drug-related data sets related to drug side effects and pharmacological data, it has become possible to predict potential drug-target interactions. The difficulties of developing computational methods for the prediction of such potential interactions lie in the rarity of known drug-protein interactions and no experimentally verified negative drug-target interaction sample. Furthermore, target proteins need also to be predicted for some new drugs without any known target interaction information. In addition, drug instances may have multiple entities of one entity type. For example, a drug may have one or more targets and one or more pathways of different types, which requires specific classification algorithms, such as multi-label classification to handle such problems.
II. LITERATURE SURVEY
Csermely et al [19] wrote a comprehensive assessment of the analytical tools of network topology and dynamics. They summarized the state-of-the-art use of chemical similarity, protein structure, protein-protein interaction, signaling, genetic interaction and metabolic networks in the discovery of drug targets. Takigawa et al [6] developed a fast, scalable algorithm for mining significantly co-occurring subgraphsubsequence pairs from drug-target interactions. Their method allowed the grouping of drug-target interactions into clusters, covering approximately 75% of interactions containing approved drugs. These clusters were highly exclusive to each other, being statistically significant and logically implying that each cluster corresponds to a distinguished type of polypharmacology. Kim, Jin, and Lee [20] [21] performed a systematic analysis of the correlation between drug side effects and protein domains, which they call "pharmacogenomic features," based on the drug-target interaction network. Chen and Zhang [22] developed a semisupervised learning method NetCBP to predict drug-target interaction using labeled and unlabeled interaction information. Assuming coherent interactions between the drugs ranked by their relevance to a query drug, and the target proteins ranked by their relevance to the hidden target proteins of the query drug, they formulate a learning framework maximizing the rank coherence with respect to the known drug-target interactions.
Gao et al [23] proposed a novel prediction method based on drug/compound ontology information extracted from ChEBI to identify drugs target groups from which the kind of functions of a drug may be deduced. Gönen [24] proposed a novel Bayesian formulation that combines dimensionality reduction, matrix factorization and binary classification for predicting drug-target interaction networks using only chemical similarity between drug compounds and genomic similarity between target proteins. Yamanishi et al [25] investigated the relationship between the chemical space, the pharmacological space and the topology of drug-target interaction networks, and show that drug-target interactions are more correlated with pharmacological effect similarity than with chemical structure similarity. In addition, they developed a new method to predict unknown drug-target interactions from chemical, genomic and pharmacological data on a large scale. [26] developed three supervised inference methods to predict Drug-Target Interactions and used for drug repositioning, namely drug-based similarity inference (DBSI), target-based similarity inference (TBSI) and network-based inference (NBI). In addition, Yu et al [27] reported a systematic approach that efficiently integrates the chemical, genomic, and pharmacological information for multi drug targeting and discovery on a large scale, based on two powerful methods of Random Forest (RF) and Support Vector Machine (SVM). Finally, Singh-Blom et al [28] presented two methods for predicting gene-disease associations based on functional gene associations and gene-phenotype associations in model organisms, which is close to this work. Those methods are: the Katz measure, used in social network link prediction, and CATAPULT (Combining dATa Across species using Positive-Unlabeled Learning Techniques, a supervised machine learning method that uses a biased support vector machine, where the features are derived from walks in a heterogeneous gene-trait network.
III. METHODOLOGY

A. Datasets
The dataset used in this work is collected from various databases, such as Drugbank. In this work, 440 drugs are used with 12 interaction types. Those interaction types are bleeding risk, urokinase, anemia risk, theophylline, serious infections, immunosuppressive, gastrointestinal ulceration, bleomycin effect, neuropathy, alteplase, serum concentration, and secretin effect. Number of pathways in this study is 60 (161 instances), having three pathway types: amino acids, carbohydrates, and metabolic other acids as classified by Kegg Brite. Each drug may have one or more pathways of action pathways, disease pathways, and metabolic pathways. Sometimes it does not have any data. In the current paper, only metabolic pathways are considered.
For example, for the drug Biotin has 14 metabolic pathways, 9 targets, and 45 disease pathways, as shown in Figure 2 . 
B. Heterogeneous Networks
Multi-dimensional mining with a focus on homogenous data, such as directed graph alignment [30] , undirected graph alignment [31] , relational data mining [32] , social networks mining [33] are several examples. Recently, such approaches found applications in computational biology [34] [35] [36] . However, they have their own limits due to the high complexity of biological networks. In addition, biological networks, social networks, information networks, systems biolgogy, and communication networks include heterogeneous information that give more insights into networks. The extraction of subnetworks (or patterns) involves several relations between the objects of interest, where each such relation is given as a network. The complexity of a particular mining problem increases with the varied nature of the networks, their number, their size, the topology of the requested pattern, and the criteria to optimize [37] . Fertin, Mohamed-Babou, and Rusu [38] presented two networks, respectively, as a directed acyclic graph and an undirected graph, on the same vertex set. In addition, they proposed heuristic and a branch-and-bound algorithm for subnetwork mining.
C. Multi-label Classification
Multi-label classification is a challenging problem in many real-world application domains, where each instance can be assigned simultaneously into multiple classes. A typical application of multi-label classification is bioinformatics and drug discovery informatics. For instance, a protein can have one or more functions and a drug can interact with one or more protein targets and have more than one pathway, as illustrated in Figure 2 . A pathway can be a drug action pathway, a disease pathway, and a metabolic pathway. In each case, a drug can have one or more drug action pathway, one or more disease pathway, and one or more metabolic pathways. Many methods for multi-label classification have been proposed in the literature.
There are mainly two methods for multi-label classification problems: (1) problem transformation method and (2) algorithm adaptation method. Problem transformation method transfers multi-label problems into single label problems. Algorithm adaptation method extends specific learning algorithm to handle multi-label problems or develop new algorithms to solve this problem. In [39] , three algorithms based on the concept of Predicting Clustering Trees (PCT) to deal with HMC problems are compared, namely Clus-HMC [40] , Clus-SC and Clus-HSC. As in [41] , the authors employ the Euclidean distance as the proximity measure for creating PCTs. The work of Aleksovski et al [42] investigates the use of other proximity measures, such as Jaccard, SimGIC and ImageClef. Ensemble of PCT-based classifiers is also investigated in [43] [44] [45] . Sangsuriyun et al [46] propose a global method for HMC, namely Hierarchical Multi-Label Associative Classification (HMAC). Guo and Gu proposed in [47] a multi-label classifier based on conditional dependency networks, where their work showed very good results; hence, their work is somewhat relevant to this paper. However, Zhou and Liu [48] presented an activity-edge centric multi-label classification framework for analyzing heterogeneous information networks with three unique features.
D. Probabilistic Heterogeneous Network Multi-label Classifier
The problem of mining drug-related data relies in the data representation and how to perform the prediction tasks accurately. The overall procedure is shown in Figure 3 . In the current work, the data is represented as a directed graph, denoted G. G = {V, E}, where V represents the common vertex set and E represents the set of directed edges between vertices with a distribution P = {p(fi|pa i ), ∀ i } [47] over a set of random variables F= {F 1 , F 2 , …,F m } and m is the number of variables. Each variable f i corresponds to one node v i V. The parents of f i , denoted as Pai, are the set of nodes vj such that (v j , v i ) ∈ E. The array of class of events is denoted as an array of Boolean variables C= (C 1 , …, C n ), which expresses whether each class label is relevant or not for the given instance. Thus, C takes its values in {0, 1}n. An instantiation of class events is denoted as c= {c 1 , …, c n }; an instantiation of the features is denoted as f = (f 1 , …, f m ). A set of complete training instances S = {(c|f)} is supposed to be available. In this case, F represents the set of drugs D and their features and C are pathways. The joint probability distribution (JPD) of F can then be written as (as in Bayesian probability):
(f i |Ci) (1) Features considered for each drug are the chemical structure drug similarity, drug-drug interactions, and proteinprotein similarity; the whole procedure is illustrated in Figure  3 and the algorithm is shown in Table 1 . 
IV. EXPERIMENTAL RESULTS
Prediction of multi drug-pathways is performed using the HNMC algorithm. The dataset is described previously in section 3. Multiple-label classification is based on chemical structure similarity, based on drug-drug interaction including their interaction type (DDI), and based on drug-pathway interactions (DPI) is accomplished. Table 2 shows parts of the datasets taken for drug-drug interactions; Table 3 shows parts of drug-pathways taken in this study.
The results of prediction accuracy, precision, recall, F1 measure, where precision is computed as in equation (2), Recall as in equation (3), F1-measure as in equation (4) Table 4 , one can see results of the proposed algorithm. An average of 90% precision, 92.35% recall, 92% accuracy, and 96% ROC were obtained. Drugs side effects affect our health tremendously. Drugrelated information is very important to mine in order to discover hidden relations such as multi drug -pathways, multidrug targets, and drug-disease relations. In this work, a probabilistic heterogeneous network multi-label classifier was proposed to classify multi drug-pathways.
Two datasets were considered: one is based on Drug-Drug Interaction (DDI) and the other was based on Drug-Pathways Interactions (DPI). With an average of 90% precision, 92.35% recall, 92% accuracy, and 96% ROC were achieved. Future work includes enlarging the datasets for drug-pathway prediction and applying this algorithm on Mapreduce since the data is very huge and big data requires reducing the functions to be performed. In addition, mining the other parts of drug network to discover hidden knowledge in drug-disease and multi drug-targets will be considered. 
